Cervomed Inc (CRVO) - News Archive

Lewy Body Dementia (DLB) represents one of the most challenging neurodegenerative conditions, characterized by cognitive fluctuations, visual hallucinations, and motor symptoms. Efforts to develop effective pharmacologi...

CervoMed, a biopharmaceutical company focused on innovative therapies for neurodegenerative diseases, recently announced the topline results from its Phase 2b clinical trial, dubbed RewinD-LB, which investigated the eff...

In an ambitious move to bolster its pioneering efforts in neurodegenerative disease research, CervoMed has announced a series of key senior leadership appointments. These strategic hires, focused on enhancing scientific...

In the ever-evolving field of neurodegenerative research, CervoMed Inc. has emerged as a beacon of hope following its recent presentations at the 17th Clinical Trials on Alzheimer’s Disease Conference (CTAD). The compan...

Dementia with Lewy bodies (DLB), a progressive neurodegenerative disorder, presents a considerable challenge in the realm of medical research and treatment, primarily due to its complex pathology and overlapping symptom...

In the esteemed corridors of medical inquiry, CervoMed Inc. has declared its imminent ascendance in the realm of neuropharmaceutical research, revealing plans to deliver late-breaking oral presentations at the forthcomi...

:Over recent years, significant advancements in our understanding and treatment of age-related neurologic disorders, particularly Dementia with Lewy Bodies (DLB), have been made. In light of a recent feature in Fortune...

Corporate Update: CervoMed s Progress in Alzheimer s Drug Development Amidst Financial Fluctuations Completed Enrollment in RewinD-LB Phase 2b Clinical TrialCervoMed recently achieved a significant milestone with the co...

In recent years, the need for effective therapies targeting neurodegenerative diseases, specifically those within the spectrum of dementia, has reached an urgent peak. Among them, Dementia with Lewy bodies (DLB) stands...

CervoMed s Strategic Appointment of William Elder as CFO Signals Promising Future for Neurologic Disorders TreatmentCervoMed Inc., a renowned clinical stage company dedicated to the development of treatments for age-rel...

CervoMed Secures Major Funding with Leading Healthcare InvestorsIn a recent development, CervoMed, a prominent player in the healthcare sector, has announced its successful completion of a private placement financing ro...

CervoMed, a renowned pharmaceutical company, unveiled groundbreaking findings at the AD/PD 2024 conference regarding the potential of their drug candidate, Neflamapimod, in treating Tau-mediated diseases. These diseases...

CervoMed, a renowned biopharmaceutical company, has recently published positive findings from the AscenD-LB Phase 2a trial in a reputable peer-reviewed journal. This critical breakthrough offers new hope for patients su...